First Albany Capital to Host Chronic Pain Conference; The Conference Will Delve into Recent Developments, Key Trends, and Investment Opportunities in the Chronic Pain Market

Perspectives and insights will be provided by leading experts inthe clinical and research and development fields and those involved incaring for patients afflicted with chronic pain. A physician panel ofexperts will host discussions on unmet needs in opioid therapy,dealing with opioids' side effects, safer non-steroidalanti-inflammatory drugs (NSAIDs), and novel agents in development forcentral pain syndromes.

"The chronic pain market will likely undergo a major sea changeover the next few years and there are significant investmentopportunities yet to be recognized," explained Adam Greene, SpecialtyPharmaceutical Analyst for First Albany Capital.

The conference will feature commentary and perspective by a panelof physician pain management experts, including Nathaniel Katz, MD,Assistant Professor of Anesthesia, Tufts University School ofMedicine; Andrew G. Kaufman, MD, Director, University HospitalComprehensive Pain Center, University of Medicine and Dentistry of NewJersey; Subhash Jain, MD, Founding Chief of Pain Service, MemorialSloan-Kettering Cancer Center; and Marco Pappagallo, MD, Director,Division of Chronic Pain, Beth Israel Medical Center.

Senior executives from 11 publicly traded biopharmaceuticalcompanies that are developing novel product candidates or formulationswill be presenting, including Adolor Corporation, Corgentech, CypressBioscience, DOV Pharmaceutical, Elite Pharmaceuticals, EndoPharmaceuticals, New River Pharmaceuticals, NicOx, Pain Therapeutics,POZEN, and Progenics Pharmaceuticals.

The conference will commence on March 16 at 9:30 AM and concludeat 4:00 PM. The Harvard Club is located at 35 West 44th Street, NewYork City.

About First Albany

Founded in 1953, First Albany is a leading institutionally focusedindependent investment bank. Through its Equity Capital Markets,Municipal and Taxable Fixed Income Divisions, as well as itssubsidiary Descap Securities, First Albany focuses on serving theinstitutional market, the growing corporate middle market and publicinstitutions by providing clients with strategic, research-based,innovative investment opportunities. First Albany offers a diverserange of products and advisory services in the areas of corporate andpublic finance, as well as fixed income and equity sales and trading.FA Technology Ventures is a leading early stage investor, providingventure capital, management and guidance for companies in the emerginggrowth sectors of information technology and energy technology. FirstAlbany is traded on Nasdaq under the symbol FACT with offices in majorbusiness and commercial markets.